# Management of Decompensated HCV Cirrhotic Patients

> **NCT03547895** · NA · COMPLETED · sponsor: **Zagazig University** · enrollment: 80 (actual)

## Conditions studied

- Decompensated Cirrhosis

## Interventions

- **DRUG:** Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)
- **DRUG:** vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion

## Key facts

- **NCT ID:** NCT03547895
- **Lead sponsor:** Zagazig University
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2016-05-24
- **Final completion:** 2018-06-24
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547895, "Management of Decompensated HCV Cirrhotic Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03547895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*